Page 9 - Clinical Program News Today

"I've seen how much they can help. I've seen the difference that they make."

Advancements in COVID-19 and Cancer Vaccine Programs Amid Increased R&D Spending

– Based on FDA confirmation in August 2023 that the ongoing Phase 1/2 single-arm study of PRGN-2012 in RRP will serve as the pivotal study to support BLA...

Record Quarterly Net Revenue of $50 Million for Q3 2023, Up 48% from Q3 2022Raises Full-Year 2023 Net Revenue Guidance from $185 to $195 Million to $194 to $198 MillionOperating Use of Cash in Q3 of $0.9 Million, Demonstrating Continued Progress Towards Achieving Profitability1 with Existing Liquidity“Extra-Strength...

Record Quarterly Net Revenue of $50 Million for Q3 2023, Up 48% from Q3 2022 Raises Full-Year 2023 Net Revenue Guidance from $185 to $195 Million to $194 to $198 Million Operating Use of Cash...

Evolus, Inc. , a performance beauty company with a focus on building an aesthetic portfolio of consumer brands, today reported financial results for the third quarter ended September 30, 2023. "The record results of our third quarter reflect the...

- Patients in OPTIC continue to experience long-term benefit from Ixo-vec through 3 years of follow-up, including maintenance of vision, durability of...

- Patients in OPTIC continue to experience long-term benefit from Ixo-vec through 3 years of follow-up, including maintenance of vision, durability of anatomical improvements and sustained reduction in anti-VEGF

- Patients in OPTIC continue to experience long-term benefit from Ixo-vec through 3 years of follow-up, including maintenance of vision, durability of anatomical improvements and sustained reduction...

- Patients in OPTIC continue to experience long-term benefit from Ixo-vec through 3 years of follow-up, including maintenance of vision, durability of anatomical improvements and sustained reduction in anti-VEGF treatment burden - - 84% reduction in annualized anti-VEGF injections, with 53% of the participants at the 2E11 dose entirely free of injections at year 3 - - Durable aflibercept protein levels up to 4.5 years after a single Ixo-vec IVT injection - - Ixo-vec continues to be generally wel